BioTech

Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD

May 08, 2026 — 03:11 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting dose for the treatment of early Alzheimer's disease.

The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.

The FDA requested additional information during the review process and has not raised any concerns about the drug's approvability as a starting dose, the companies said.

LEQEMBI has been approved in more than 50 countries for the treatment of early Alzheimer's disease.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

BioTech
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

BIIB

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.